Miramoon Pharma is a Spanish biotech developing small-molecule neuroprotective drugs that stabilise intracellular calcium and protect cells against oxidative stress, aiming to halt or slow degeneration in rare and neurodegenerative disorders. Its lead candidate MP-004, a novel FKBP12 ligand, targets retinitis pigmentosa and other inherited retinal diseases, with additional programmes in skeletal/cardiac muscle disease and CNS conditions such as ALS. Founded in 2019 as a spin-off of the University of the Basque Country (UPV/EHU) and the Biogipuzkoa (formerly Biodonostia) Health Research Institute, it is seed/angel-stage and backed by Banco Sabadell's BStartup10 and Pinama Inversiones. It is headquartered in Donostia-San Sebastián.
Develops small-molecule, mitochondria-targeted drugs that protect cells against oxidative stress in rare diseases, including retinal and muscle indications. Like Miramoon, it plans to out-license or commercialise its assets.
Clinical-stage biotech developing an oral small molecule (gildeuretinol) to slow degeneration in inherited retinal disease (Stargardt). It is the same rare-retina, small-molecule, asset-value model.
Develops Rycal small molecules that stabilise the ryanodine receptor/FKBP12 complex to fix intracellular calcium leak in skeletal and cardiac muscle disease. This is the same mechanism and indication logic as MP-004.
Develops an oral antioxidant small molecule (NPI-001) to slow cone degeneration in retinitis pigmentosa. This is a direct match on indication and on its oxidative-stress neuroprotection approach.
Develops small molecules for retinitis pigmentosa that are gene-agnostic, so they can work across inherited retinal diseases. Like Miramoon, it runs a mutation-independent small-molecule programme.
M
A
A
N
E
